36 results about "Dioleoyl phosphatidylcholine" patented technology

The invention relates to a cucurbitacin liposome composition and its preparation, which has rather high encapsulation efficiency, and can be administered through vein, muscle, oral and nasal. The constituent percentage by weight of the composition are, cucurbitacin BE or cucurbitacin B 0.001-0.1%, phospholipids 0.1-10%, cholesterin 0-5%, the phospholipids can be lecithin, di-stearoyl phosphatidyl choline, di- palmityl phosphatidyl choline, di-oleoyl phosphatidyl choline, di- palmityl phosphatidyl ethanolamine, di-stearoyl phosphatidylglycerol. The preparation according to the invention can be prepared in the form of injection, oral liquid, syrup, drop and nasal spray

The invention discloses an olmesartan liposome solid preparation prepared by the following raw and supplementary material components in parts by weight: 1 part of olmesartan, 2.5-14 parts of dioleoyl-phosphatidylcholine, 0.5-6 parts of cholesterol, 0.8-10 parts of sodium glycyl-cholate, 0.2-5 parts of soy sterol and 2-20 parts of pharmaceutically acceptable carriers or excipients. The liposome solid preparation provided by the invention has high entrapment rate, even grain size, long medicament retention time in blood circulation, simple equipment, easiness in operation, improved product quality of the preparation and lessened toxic and side effects and is suitable for industrial production.

The invention discloses rabeprazole sodium liposome enteric-coated tablets and a preparation method and application thereof to treating gastroesophageal reflux disease (GERD). The rabeprazole sodium liposome enteric-coated tablets comprise rabeprazole sodium liposome solid, alkaline substances and other common auxiliary materials for a solid preparation, wherein the rabeprazole sodium liposome solid comprises the following components in part by weight: 10 to 20 parts of rabeprazole sodium, 40 to 90 parts of dioleoyl phosphatidylcholine, 15 to 50 parts of cholesterol and 8 to 30 parts of sodium glycocholate. The rabeprazole sodium liposome enteric-coated tablets have the advantages of improving stability, increasing dissolution, solving the problem of color change when being heated, and the like, and when the rabeprazole sodium liposome enteric-coated tablets are used for treating the GERD, the curative ratio is higher, the total effective rate is higher, and the clinical superiority is more obvious.

The invention discloses a compound soft capsule containing an acanthopanax extract for strengthening the brain and a preparation method of the compound soft capsule. The method comprises the following steps: orderly dissolving the acanthopanax extract, mixed phospholipid and vegetable oil into an ethanol solution of poloxamer, removing ethanol to obtain content of the soft capsule; and encapsulating the content into a soft capsule shell, wherein the dosage of the mixed phospholipid is 90-240 parts by weight, the dosage of the vegetable oil is 140-300 parts by weight and the dosage of the poloxamer is 10-50 parts by weight relative to 100 parts of acanthopanax extract, the mixed phospholipid is prepared from an animal brain extract and adding ingredients, the weight ratio of the animal brain extract to the added ingredients is 1:(2-6) and the added ingredients comprise phosphatidylserine and/or dilinoleoyl phosphatidylcholine. The compound soft capsule for strengthening the brain, which is disclosed by the invention, can be effectively used for assisting improvement of memory, improvement of sleeping, and prevention of senile dementia, and has a good health-care effect.

The invention relates to the field of pharmaceutical preparation, in particular to hydrochloric acid boanmycin liposomes and a preparation method thereof. The hydrochloric acid boanmycin liposome comprises the hydrochloric acid boanmycin liposomes, phospholipids, cholesterin, citric acid, and sodium citrate, gradient regulator which respectively have the following mass percent: 0.5-3.0%, 3-30%, 1-10%, 0.5-3%, and 1-5%. The phospholipids is lecithin, double stearoyl phosphatidyl choline (DSPC), dipalmitoyl phosphatidyl choline (DPPC), dioleoyl phosphatidyl choline (DOPC) and the like. The invention is prepared by adopting the PH gradient method. Compared with the prior art, the hydrochloric acid boanmycin liposomes of the invention can reduce dosage, toxic side effect on human body and production cost and has the advantages such as targeting at some specific organs. The hydrochloric acid boanmycin liposomes of the invention can be prepared into parenteral solution or further prepared into freeze-dried powder hydrochloric acid boanmycin liposomes by adding a supporting agent.

The invention relates to a method for improving dilinoleoyl phosphatidylcholine (DLPC) content with an enzyme method. The invention belongs to the technical field of phospholipid. According to the invention, soybean PC-90 is adopted as a raw material; the raw material, linoleic acid and immobilized lipase are added to a certain organic phase, and an enzymatic acidolysis reaction is carried out; after desolvation, a target product is extracted by using chloroform/methanol (2/1, V/V); immobilized lipase is recovered by centrifugation; desolvation is carried out, and acetone washing and desolvation are carried out, such that the product with a DLPC content higher than 60% (HPLC normalization method) is obtained.

The invention relates to the technical field of biological medicines, in particular to a pH-sensitive liposome as well as a preparation method and application thereof. The pH-sensitive liposome is prepared from the following medicines and a liposome carrier according to the following amount of substance: (2, 3-dioleoyl-propyl)-trimethyl ammonium-chloride salt, dioleoyl phosphatidylcholine, cholesterol succinic acid monoester and DSPE-PEGn-pep in a molar ratio of (2 to 5): (0.5 to 1.5): (0.5 to 1.5): (0.1 to 0.3), the total mass ratio of the ICD inducer to the (2, 3-dioleoyl-propyl)-trimethyl ammonium-chloride salt, the dioleoyl phosphatidylcholine and the cholesterol succinic acid monoester is (5-12): 100; the mass ratio of the adenosine pathway blocking agent to the ICD inducer is (0.5-2): (0.5-3). The ICD inducer and the adenosine pathway inhibitor are combined for use, so that the problems that the anti-tumor curative effect is poor and tumor immunity escapes when only the ICD inducer is used for treatment are solved, and in-vivo co-delivery of the ICD inducer and the adenosine pathway inhibitor is realized by utilizing the liposome carrier; the pH sensitive characteristic of the POL effectively ensures that the POL is kept stable in the blood circulation process.

The invention relates to a preparation method and application of self-assembled nano-drug liposome for resisting Alzheimer's disease, and can effectively solve the problems of low blood-brain barrier penetration rate and poor treatment effect of the traditional Alzheimer's disease treatment medicine. The preparation method comprises the following steps: dissolving a hydrophobic anti-inflammatory drug in absolute ethyl alcohol, adding into water, and violently stirring to obtain the self-assembled hydrophobic anti-inflammatory nano particle drug; and dissolving dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, cholesterol and T7 peptide-polyethylene glycol-phosphatidyl ethanol amine in trichloromethane to form a solution, adding the solution into trichloromethane, carrying out reduced pressure distillation to form a thin film, continuously carrying out rotary evaporation, adding the self-assembled hydrophobic anti-inflammatory nano particle drug, dispersing the thin film, and carrying out ultrasonic detection to obtain the self-assembled nano-drug liposome for resisting the Alzheimer's disease. The preparation method is stable, reliable and low in cost, plays a huge role in preparing the medicine for treating the Alzheimer's disease, enhances the effect of treating the Alzheimer's disease, and is an innovation of the medicine for treating the Alzheimer's disease.

The invention belongs to the field of phospholipid processing, and particularly relates to a method for preparing high-purity dilinoyl phosphatidylcholine through combination of enzymatic modification and reversed-phase column chromatography separation and a product of the high-purity dilinoyl phosphatidylcholine. According to the method, high-purity phosphatidylcholine (PC) and linoleic acid are used as raw materials, an ultrasonic continuous flow cell crusher is adopted to pre-mix a substrate and lipase before lipase reaction, the reaction product of the system is subjected to acetone desolvation to obtain an acetone insoluble substance rich in dilinoyl phosphatidylcholine, the acetone insoluble substance is added to a chromatographic column with C18 as a stationary phase, and eluting is carried out with low-carbon alcohol or a low-carbon alcohol-water solution to obtain a DLPC product with the purity of more than 95% and the yield of more than 65%. The preparation method disclosed by the invention is mild in condition, efficient, simple and controllable in operation and easy to realize industrial production, and the dilinoyl phosphatidylcholine obtained by the method is high in purity and high in yield and can be an important source of high-purity dilinoyl phosphatidylcholine in the medicine and health care industry.

The invention belongs to the field of phospholipid processing, and particularly relates to a method for separating and purifying dilinoleoylphosphatidylcholine and a dilinoleoylphosphatidylcholine product. The method comprises the following steps: (1) preparation of a sample loading solution: dissolving high-purity phosphatidylcholine into low-carbon alcohol to obtain a sample solution; and (2) separation and purification: carrying out separation and purification on the sample solution by adopting a reversed-phase column system, then carrying out elution, collecting an eluent, and then carrying out low-fat desolvation on the eluent to obtain the dilinoleoylphosphatidylcholine product. According to the invention, the DLPC content is greatly increased, the purity is increased from 30% to 90% or above, and the recovery rate is higher than 70%; the low-carbon alcohol or the low-carbon alcohol water solution is used as the eluent, so that recycling is facilitated, and the process is green and environment-friendly; and the preparative chromatographic column is adopted for separation and purification, so that the separation capacity is high, repeatability is good, operation is easy and controllable, and industrial production is easy to achieve.

The invention discloses a Shuxuening lipidosome injection. The Shuxuening lipidosome injection is mainly prepared by using a ginkgo biloba extract, dioleoylphosphocholine, octadecylamine, polyoxyethylene alkylamine, sodium metabisulfite and sodium chloride. Compared with the prior art, the Shuxuening lipidosome injection disclosed by the invention is suitable for large-scale industrial production and has the advantages that the stability and bioavailability of a preparation are greatly improved, product quality is improved and toxic and side effects are reduced.

The invention discloses a soft capsule containing a silybum marianum extract and a preparation method of the soft capsule. The content of the soft capsule contains the following raw materials in parts by weight: 1 part of silybum marianum extract, 45-115 parts of medium chain triglycerides, 40-120 parts of edible oil and 140-300 parts of phospholipid relative to 1 part of silybum marianum extract; the unsaturated fatty acid content in the edible oil is not smaller than 70wt%; the content of phosphatidylcholine in the phospholipid is 20-80wt%; the content of the dilinoleoyl phosphatidylcholine is 20-80wt%. The preparation method of the soft capsule disclosed by the invention comprises the following steps: mixing the components to obtain the content of the soft capsule, and encapsulating the content into a soft capsule shell. By adopting the soft capsule disclosed by the invention, liver injury can be effectively improved, blood fat is reduced, and the active components such as the silybum marianum extract and the phospholipid in the soft capsule can stably exist for a long period of time.